Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02314689 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease
A Phase 1 study, sponsored by Suvankar Majumdar.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02314689 is a Phase 1 study that has completed, run by Suvankar Majumdar. The registered enrollment target is 4 participants.
The verdict
NCT02314689, a Phase 1 study, has completed, sponsored by Suvankar Majumdar.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the maximum tolerated dose, safety and pharmacokinetics of an investigational drug, intravenous (IV) citrulline, in subjects in steady-state sickle cell disease.
Interventions
- DRUG Intravenous (IV) citrulline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02314689
The ClinicalTrials.gov registry entry for NCT02314689 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suvankar Majumdar, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravenous (IV) citrulline is the first listed.
NCT02314689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02314689 about?
NCT02314689 is a clinical study titled "A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease". The purpose of this study is to assess the maximum tolerated dose, safety and pharmacokinetics of an investigational drug, intravenous (IV) citrulline, in subjects in steady-state sickle cell disease.
What is the current status of trial NCT02314689?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-01. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02314689?
The interventions under investigation include: Intravenous (IV) citrulline (DRUG).
Who is sponsoring clinical trial NCT02314689?
This trial is sponsored by Suvankar Majumdar, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.